Ctrl

K

Lanadelumab

Class
Kallikrein inhibitors
Subclass
Anti-Kallikrein monoclonal antibodies
Substance name
Lanadelumab, lanadelumab-flyo
Brand names
Takhzyro®
Common formulations
Solution for injection
Dosage and administration
Adults patients
Prevention of attacks of hereditary angioedema
Start at: 300 mg SC q2 weeks
Maintenance: 300 mg SC q2-4 weeks
Indications for use
Labeled indications
Adults
Prevention of attacks of hereditary angioedema
Pregnancy and breastfeeding
Breastfeeding
Acceptable for use during breastfeeding.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource